Premier Diagnostic Center – Burnaby

3185

PET/CT in Canada

In B.C. an estimated 23,700 people were diagnosed with cancer in 2013 of which at least 10,000 could benefit from PET/CT.  Our medical system capacity is approximately 3,000 scans on each of the two scanners at the BC Cancer Agency's Vancouver facility.  These government figures demonstrate the potential demand for PET/CT.

In addition, as a private facility we have attracted the attention of researchers across the country.  We will soon be embarking on new clinical trials including an Alzheimer's and Parkinson's PET research study, as well as a choline based PET pharmaceutical trial for advanced pancreatic, prostate, and colorectal imaging.

Premier Diagnostic Centers – China

MRI BJ 3

Premier Diagnostic Health

We are developing and operating diagnostic imaging clinics in China, providing advanced imaging technology that improves patient treatment and outcomes.

The Chinese middle class is expanding at a rapid rate, increasing discretionary spending ability, which includes demand for a wide range of Western medical diagnostic services. The central government has recognized this trend and recently has encouraged direct foreign investment in the health care sector. Accordingly, there is an increased demand for PET/CT, the gold standard in cancer detection, and high-end MRI.

Our China MRI Center in Beijing has exceeded our goals and expectations due to our efficient management protocols and huge demand, exceeding 1100 scans per month in 2014.

Sequant Re Holdings

Sequant Re Logo

Sequant Re

Sequant Re provides reinsurance brokers and buyers of reinsurance access to flexible collateralised reinsurance and retrocession solutions for their risk transfer needs. We are able to provide peace of mind fully collateralised protection at efficient costs for deals of all sizes.

For investors, the emerging convergence market offers a broad spectrum of opportunities for diversifying returns. Sequant Re will guide investors into the selection of the right transactions for their risk tolerance and yield expectations. Investors with Sequant Re’s platform benefit from lower cost of execution, lower barriers to entry, and portfolio management options.

Latest News

  • $7.2M PRIVATE PLACEMENT

    Premier Diagnostic Health Services Inc. (“Premier” or the “Company”) (CSE: PDH) is pleased to announce a non-brokered private placement offering (the “Offering”) of common shares...

  • New President and CEO

    PREMIER DIAGNOSTIC HEALTH SERVICES INC. ANNOUNCES NEW PRESIDENT AND CEO Premier Diagnostic Health Services Inc. (“Premier” or the “Company“) (CSE: PDH) is pleased to announce...

  • New Chair Of The Board

    Premier Diagnostic Health Services Inc. (“Premier” or the “Company”) announces that the Board of Directors has appointed distinguished clinician and scientist Dr. Simon Sutcliffe, M.D.,...

  • New Director and Officer Appointments and Option Grant

    Premier Diagnostic Health Services Inc. (“Premier” or the “Company”) is pleased to announce the appointment of a new member to its board of directors and...